Rexahn announced that it has submitted a Phase 2 protocol to the FDA for the study of Serdaxin for the treatment of Parkinson’s disease (PD). The planned double blind, randomized, placebo-controlled trial will include the Unified Parkinson’s Disease Rating Scale (UPDRS) and quality of life instruments as study endpoints. It will be conducted at multiple sites in approximately 300 patients.
Serdaxin is a dual serotonin and dopamine enhancer being evaluated as a potential treatment for multiple CNS disorders where these neurotransmitters are depleted or implicated in CNS-based illnesses.
For more information call (240) 268-5300 or visit www.rexahn.com.